Longevity therapeutics is an emerging field in biopharma focused on targeting the biological mechanisms of aging to prevent or treat multiple age-related diseases. Rather than addressing individual conditions in isolation, this approach aims to extend healthspan—the number of years people live in good health—by addressing the underlying drivers of aging.

Recent advances in aging biology, combined with progress in artificial intelligence, data science, and increased investment, have accelerated the development of longevity-focused drug programs. Researchers are now exploring a range of biological pathways linked to aging, including cellular senescence, epigenetic reprogramming, inflammation, mitochondrial dysfunction, and loss of proteostasis. These mechanisms are helping shape new therapeutic strategies and drug discovery approaches.

While aging itself is not currently an approved medical indication, longevity therapies typically enter clinical development through specific disease areas such as neurodegeneration, metabolic disorders, cardiovascular disease, and other age-related conditions. This indication-first approach allows companies to generate clinical evidence while building a broader platform for addressing aging biology.

The growing ecosystem of biotechnology companies, investors, and pharmaceutical partners reflects strong momentum in the field. As longevity science advances, the focus is shifting from understanding aging to translating discoveries into regulated medicines that can improve long-term health outcomes.

Download our report to explore the latest trends, scientific developments, and investment activity shaping the future of longevity therapeutics.